Levoamlodipine Besylate Tablets

Amlodipine besylate is a dihydropyridine calcium antagonist (calcium ion antagonist or slow channel blocker). The contraction of myocardial and smooth muscle depends on the entry of extracellular calcium ions into cells through specific ion channels. This product selectively inhibits the transmembrane entry of calcium ions into smooth muscle cells and myocardial cells, and its effect on smooth muscle is greater than that on myocardium. Its interaction with calcium channels is determined by the progressive rate of its binding and dissociation from receptor sites, so the pharmacological effect is gradually produced. This product is a peripheral artery dilator that acts directly on vascular smooth muscle, reduces peripheral vascular resistance, and thus lowers blood pressure. At therapeutic doses, negative inotropic effects can be observed in in vitro experiments, but not in whole animal experiments. This product does not affect plasma calcium concentration. 15 randomized, double-blind, placebo-controlled clinical trials have confirmed the antihypertensive effect of this product.

The main ingredients and chemical names of this product are: (-) 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulfonate

This product is white tablets.

1 Hypertension (used alone or in combination with other drugs). 2 Angina pectoris: especially spontaneous<Aclass=bluehref=http://zzk.39.net/zz/xiongbu/a66b7.htm

The usual starting oral dose is 5 mg, once a day, and the maximum dose is no more than 10 mg, once a day. Thin people, those with weak constitutions, elderly patients, or those with impaired liver function should start taking the drug from 2.5 mg, once a day; those who take other antihypertensive drugs in combination should also start taking the drug from this dose. The dosage is adjusted according to individual needs, and the adjustment period should be no less than 7-14 days so that the doctor can fully evaluate the patient's response to the dose. However, under the premise of clinical guarantee, the adjustment speed can be accelerated. The recommended dose for the treatment of angina pectoris is 5-10 mg, and the elderly patients or those with impaired liver function need to reduce the dose.

1 If you feel unwell while taking this product, tell your doctor or pharmacist as soon as possible. If the situation is urgent, stop taking the medicine first. 2 If you are satisfied with the efficacy of this product. The following are possible adverse reactions, but not everyone will definitely experience them. You may not encounter any of them, so don't worry

Allergic to dihydropyridine calcium antagonists.

Precautions for children: There is no data on the use of this product in children. Precautions for pregnancy and lactation: This product is recommended only when there are no other safer alternatives and the disease itself poses a greater risk to the mother and child. Precautions for the elderly: Elderly patients can use normal doses. However, it is better to start with a smaller dose and then increase it gradually.

1. If you take any other medicines, please tell your doctor or pharmacist, including any over-the-counter medicines purchased from a pharmacy, supermarket or health food store. Some medicines may interfere with levamlodipine besylate, including: cimetidine, grapefruit juice, acidogens: the pharmacokinetics of this product are not changed when used together. Atorvastatin, digoxin, ethanol: this product does not affect their pharmacokinetics. Sildenafil: A single dose of sildenafil (Viagra) in patients with primary hypertension has no effect on the pharmacokinetics of this product. The two drugs produce an independent antihypertensive effect when used together. Warfarin: This product does not change the prothrombin action time of warfarin. Digoxin, phentoin and warfarin: The combination with this product has no effect on the plasma protein binding rate. Anesthetics: Inhaled hydrocarbons combined with this product can cause hypotension. Non-steroidal anti-inflammatory drugs: Indomethacin in particular can weaken the antihypertensive effect of this product. β-blockers: well tolerated when used with this product, but may cause excessive hypotension and rarely aggravate heart failure. Estrogen: co-administration may cause fluid retention and increase blood pressure. Sulfinpyrazone: co-administration may increase the protein binding rate of this product and produce changes in blood drug concentration. Lithium: co-administration may cause neurotoxicity, nausea, vomiting, diarrhea, ataxia, tremor and/or numbness, so caution is required. Sympathomimetic amines: may weaken the antihypertensive effect of this product. Sublingual nitroglycerin and long-acting nitrate preparations: co-administration with this product may enhance the anti-anginal effect. Although no rebound effect has been reported, the dose should be gradually reduced under the guidance of a doctor when the drug is discontinued. Thiazide diuretics, ACEI, digoxin, warfarin, antibiotics and oral hypoglycemic drugs: can be safely used with this product. 2 These drugs may be affected by levamlodipine besylate or affect its efficacy. You may need a different dose or need to take different drugs. Please follow your doctor's advice. 3 Physicians and pharmacists may have more information about precautions when taking levamlodipine.

Keep in a light-proof and sealed place

2.5 mg (calculated as levamlodipine)

36 months.

Jiangxi Shimei Pharmaceutical Co., Ltd.

• Founded in:

  2002-11-15

• Address:

  Dafu Industrial Park, Dongxiang District, Fuzhou City, Jiangxi Province

• Tax NO.:

  91361000744273829R

• Registered Funds:

  105 million yuan

• Website:

  Log in to view

• Email:

  Log in to view